DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 892 filers reported holding DANAHER CORPORATION in Q1 2014. The put-call ratio across all filers is 0.37 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $8,812,000 | +67.0% | 89,300 | +65.7% | 0.04% | +60.9% |
Q1 2018 | $5,277,000 | -85.7% | 53,900 | -86.4% | 0.02% | -86.6% |
Q4 2017 | $36,905,000 | +21.9% | 397,600 | +12.7% | 0.17% | +11.7% |
Q3 2017 | $30,264,000 | +62.5% | 352,800 | +59.9% | 0.15% | +42.6% |
Q2 2017 | $18,625,000 | -29.3% | 220,700 | -28.3% | 0.11% | -50.2% |
Q1 2017 | $26,343,000 | +48.8% | 308,000 | +35.4% | 0.22% | +70.9% |
Q4 2016 | $17,709,000 | +1491.1% | 227,500 | +1502.1% | 0.13% | +1487.5% |
Q3 2016 | $1,113,000 | -96.7% | 14,200 | -96.1% | 0.01% | -93.0% |
Q4 2015 | $34,003,000 | +25.8% | 366,097 | +15.4% | 0.12% | -19.0% |
Q3 2015 | $27,027,000 | +17.4% | 317,178 | +18.0% | 0.14% | +3.6% |
Q2 2015 | $23,016,000 | -17.5% | 268,907 | -18.2% | 0.14% | -35.7% |
Q1 2015 | $27,892,000 | +26.6% | 328,537 | +27.8% | 0.21% | +28.3% |
Q4 2014 | $22,027,000 | +222.6% | 256,987 | +186.0% | 0.17% | +213.2% |
Q3 2014 | $6,827,000 | +35.1% | 89,852 | +39.9% | 0.05% | +8.2% |
Q2 2014 | $5,055,000 | -76.4% | 64,207 | -77.5% | 0.05% | -73.4% |
Q1 2014 | $21,440,000 | -19.1% | 285,857 | -16.7% | 0.18% | 0.0% |
Q4 2013 | $26,497,000 | +14.7% | 343,227 | +3.0% | 0.18% | +291.5% |
Q3 2013 | $23,108,000 | +1209.2% | 333,334 | +1096.2% | 0.05% | +683.3% |
Q2 2013 | $1,765,000 | – | 27,867 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |